Background The COMMENCE trial was conducted to evaluate the safety and effectiveness
of aortic valve replacement using a bioprosthesis with novel RESILIA tissue (Edwards …

Objectives New technologies for the treatment of Aortic Stenosis are evolving to minimize
risk and treat an increasingly comorbid population. The Sutureless Perceval Valve is one …

OBJECTIVES Long-term durability of bioprosthetic valves is predominantly limited by
structural valve deterioration. RESILIA™ tissue has exhibited reduced calcification in pre …

Background The decision to implant a biological valve prosthesis is influenced by the issue
of durability. We investigated the rate and the cause of reintervention in 3 different aortic …

Background Recent studies reported higher-than-expected rates of early structural valve
degeneration (SVD) and/or reoperation of externally mounted leaflet aortic bioprosthesis …

Objective To compare the rate of structural valve degeneration (SVD) following surgical
aortic valve replacement associated with the Trifecta (TF) valve (St Jude Medical) versus …

Abstract OBJECTIVES The Carpentier Perimount (CP) Magna Ease, the Crown
Phospholipid Reduction Treatment (PRT) and the Trifecta bovine pericardial valves have …

Abstract Introduction The Carpentier‐Edwards PERIMOUNT Magna Ease valve is a third‐
generation bioprosthesis for aortic valve replacement (AVR). This is a postapproval study …

Background: Recent trials showed that TAVI is neither inferior nor superior to surgical aortic
valve replacement. The aim of this study was to evaluate the outcomes of Sutureless and …

Debido la mayor utilización de bioprótesis en los últimos años para el tratamiento de la
valvulopatía aórtica en pacientes cada vez más jóvenes y la mayor esperanza de vida; …